Relay Therapeutics is a pioneering company in the field of precision medicine, focusing on the development of small molecule therapies for cancer and genetic diseases. With a robust pipeline, including RLY-4008 targeting FGFR2 in solid tumors and RLY-2608 aimed at mutant-PI3Ka, Relay Therapeutics is at the forefront of utilizing computational modeling to revolutionize drug discovery. Additionally, its collaboration with Genentech on Migoprotafib highlights its commitment to advancing treatment options for patients with challenging diseases. Founded in 2015 and based in Cambridge, Massachusetts, Relay Therapeutics combines cutting-edge science with strategic partnerships to tackle unmet medical needs.
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
